ReviewCurrent urology reports2004
Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine.
Review in Current urology reports, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 21 citations in OpenAlex.
- Article
- Management of urinary incontinence.P & T : a peer-reviewed journal for formulary management · 2012Article
- Urodynamic study and quality of life in patients with fibromyalgia and lower urinary tract symptoms.International urogynecology journal and pelvic floor dysfunction · 2008Article
- Current trends in the evaluation and management of female urinary incontinence.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2006Review
- Solifenacin in overactive bladder syndrome.Drugs · 2006Review
- Stress urinary incontinence in women: diagnosis and medical management.MedGenMed : Medscape general medicine · 2005Review
- Female neurogenic vesicourethral dysfunction: evaluation and management.Current urology reports · 2005Review
- Improving the tolerability of anticholinergic agents in the treatment of overactive bladder.Drug safety · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This year, the US Food and Drug Administration will approve four new drugs indicated for the treatment of lower urinary tract dysfunction. Darifenacin, solifenacin, and trospium are antimuscarinic agents aimed at relieving the symptoms of overactive bladder and urge incontinence in men and women. Duloxetine will be the first drug approved for the treatment of female stress urinary incontinence. This article presents current data on the efficacy and tolerability of these new agents and invites the reader to decide whether they offer any potential advantages over existing therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.